Finance

Lists
Why is TCRX up २.४८%?
Dive Deeper
TCRX:NASDAQ
Tscan Therapeutics Inc
US$ ०.१९
+२.४८%
(+०.००४६) 1D
US$ ०.१९
+२.५४% (+०.००)
Pre-market
Closed: नोभेम्बर १०, १६:००:०० GMT-५  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TCRX...
Open
US$ ०.१९
High
US$ ०.१९
Low
US$ ०.१९
Mkt. cap
१.३० करोड
Avg. vol.
५.५३ लाख
Volume
१३२.००
52-wk high
US$ १.४७
52-wk low
US$ ०.१७
EPS
-US$ ०.९१
Beta
१.२१
Shares outstanding
६.३५ करोड
No. of employees
१३८
Open
US$ ०.१९
High
US$ ०.१९
Low
US$ ०.१९
Mkt. cap
१.३० करोड
Avg. vol.
५.५३ लाख
Volume
१३२.००
52-wk high
US$ १.४७
52-wk low
US$ ०.१७
EPS
-US$ ०.९१
Beta
१.२१
Shares outstanding
६.३५ करोड
No. of employees
१३८
News stories
From web sources and news partners
FXStreet
FXStreet
·
२ घण्टा पहिले
AI spending fears threaten S&P 500 recovery
Barron's
Barron's
·
२ घण्टा पहिले
S&P 500 Futures Up in Premarket Trading; Intercorp Finl Svcs, CoreWeave Lead
marketscreener.com
marketscreener.com
·
२ घण्टा पहिले
S&P 500, Nasdaq futures rise as CoreWeave results calm AI jitters
JournalArta
JournalArta
·
१६ मिनेट पहिले
S&P 500: Strategists See Three Reasons for a Year-End Rally
About Tscan Therapeutics Inc
CEO-
Employees१३८
Founded२०१८
HeadquartersWaltham, म्यासेचुसेट्स, संयुक्त राज्य अमेरिका
SectorHealth Care
Industry-
Websitetscan.com
Analyst ratings
Based on 6 analysts giving stock ratings to TCRX in the past 3 months
Hold
Buy
1
Hold
5
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for TCRX in the last 3 months.
Highest
Current US$ ०.१९
US$ १.०० (+४२६.८७%)
Average
US$ १.०० (+४२६.८७%)
Lowest
US$ १.०० (+४२६.८७%)
Analyst
Recommendation
Action
Price target
Projected
Date
Andres Y. Maldonado
H.C. Wainwright
Hold
Downgraded
US$ १.००
+४२६.९%
09/09/2026
Sam Slutsky
LifeSci Capital
Hold
Downgraded
-
-
09/02/2026
Gil Blum
Needham
Hold
Downgraded
-
-
09/02/2026
David Nierengarten
Wedbush
Hold
Downgraded
US$ १.००
+४२६.९%
09/03/2026
Maxwell Skor
Morgan Stanley
Hold
Maintained
-
-
08/17/2026
Tara Bancroft
TD Cowen
Buy
Maintained
-
-
08/12/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
Revenue
२५.११ लाख
२५.६७ लाख
९.८२ लाख
१०.५१ लाख
Cost of goods sold
३.१७ करोड
१.८४ करोड
२.१९ करोड
२.३४ करोड
Cost of revenue
३.१७ करोड
१.८४ करोड
२.१९ करोड
२.३४ करोड
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
७८.७४ लाख
५९.८६ लाख
८२.१७ लाख
८१.४२ लाख
Operating expense
७८.७४ लाख
५९.८६ लाख
८२.१७ लाख
८१.४२ लाख
Total operating expenses
३.९६ करोड
२.४४ करोड
३.०१ करोड
३.१५ करोड
Operating income
-३.७१ करोड
-२.१९ करोड
-२.९१ करोड
-३.०५ करोड
Other non operating income
-
-
-
-
EBT including unusual items
-३.५७ करोड
-२.३० करोड
-२.८७ करोड
-३.०४ करोड
EBT excluding unusual items
-३.५७ करोड
-२.१० करोड
-२.८७ करोड
-३.०४ करोड
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-३.५७ करोड
-२.३० करोड
-२.८७ करोड
-३.०४ करोड
Net profit margin
-१,४२२.१४%
-८९५.०९%
-२,९१९.१४%
-२,८८८.५८%
Earnings per share
-०.२८
-०.१८
-०.२२
-०.२३
Interest and investment income
२०.४१ लाख
१५.८३ लाख
११.६२ लाख
८.३३ लाख
Interest expense
-६.९९ लाख
-७.०२ लाख
-६.८९ लाख
-६.९९ लाख
Net interest expenses
१३.४२ लाख
८.८१ लाख
४.७३ लाख
१.३४ लाख
Depreciation and amortization charges
-
-
-
-
EBITDA
-३.६३ करोड
-२.११ करोड
-२.८४ करोड
-२.९८ करोड
Gain or loss from assets sale
-
-
-
९९.०० हजार
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google एपहरू